Drug Profile
Research programme: neurodegenerative disorder therapeutics - MAKScientific/Biogen
Alternative Names: MAK 1400Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator MakScientific
- Class Small molecules
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Neurodegenerative disorders
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
- 27 Oct 2017 Preclinical development is for Multiple sclerosis ongoing in the US (MAKScientifc pipeline, October 2017)